lopinavir/ritonavir accord 200 mg / 50 mg tabletti, kalvopäällysteinen
accord healthcare b.v. - ritonavir, lopinavir - tabletti, kalvopäällysteinen - 200 mg / 50 mg - lopinaviiri ja ritonaviiri
ritonavir accord 100 mg tabletti, kalvopäällysteinen
accord healthcare b.v. - ritonavir - tabletti, kalvopäällysteinen - 100 mg - ritonaviiri
tremfya
janssen-cilag international nv - guselkumab - psoriasis - immunosuppressantit - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressantit - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
viant infuusiokuiva-aine, liuosta varten
b. braun melsungen ag - ascorbic acid, biotin, colecalciferol, cyanocobalamin, riboflavin sodium fosfate, nicotinamide, pyridoxine hydrochloride, retinol palmitate, thiamine hydrochloride, all-rac-alfa-tocopherol, pantothenic acid, all-rac-phytomenadione, folic acid hydrate - infuusiokuiva-aine, liuosta varten - 932 mg - vitamiinit
cabazitaxel accord
accord healthcare s.l.u. - kabatsitakseli - eturauhasen kasvaimet, kastraatio-resistentin - antineoplastiset aineet - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
vazkepa
amarin pharmaceuticals ireland limited - icosapent ethyl - dyslipidemiat - lipidimodifioivat aineet - indicated to reduce cardiovascular risk as an adjunct to statin therapy.
cabazitaxel medical valley 60 mg / 1,5 ml infuusiokonsentraatti ja liuotin, liuosta varten
medical valley invest ab - cabazitaxel - infuusiokonsentraatti ja liuotin, liuosta varten - 60 mg / 1,5 ml - kabatsitakseli
erwinase 10000 u injektio-/infuusiokuiva-aine liuosta varten
porton biopharma limited - crisantapase - injektio-/infuusiokuiva-aine liuosta varten - 10000 u - asparaginaasi
cimzia
ucb pharma sa - sertolitsumabipegoli - crohnin tauti - immunosuppressantit - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia voidaan antaa monoterapiana, jos potilas ei siedä metotreksaattia tai metotreksaattihoidon jatkaminen on sopimatonta. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.